Metformin

Rice Harbut Elliott LLP is investigating a possible class action lawsuit, representing Canadians who were prescribed metformin containing a nitrosamine impurity called N-nitrosodimethylamine (NDMA) above the acceptable limit. Drugs containing metformin are used to treat patients with diabetes.

Current Status
Recall Information

Current Status

The Metformin Class Action is in the process of being dismissed as a result of the ruling in Palmer v. Teva Canada Limited, 2024 ONCA 220 (CanLII), https://canlii.ca/t/k3q9w. RHE will update this website to indicate the date on which the case is formally dismissed.

As of this date, class members need to take their own steps if they wish to advance their claims for Metformin related damages. Class members should be aware that limitation periods may commence running pursuant to s. 39 of the Class Proceedings Act. Class members should consider immediately seeking legal advice and assistance on:

1. Commencing their own claims in the Provincial Superior Court where they reside;

2. Contacting counsel to assist them with such claims.

As our case will be dismissed, RHE cannot provide further assistance to Metformin claimants. We encourage you to take the steps above if you believe you have an injury caused by these Defendants.

Recall Information

At present, the recall involves the following metformin products:

Company	Product name/Active Pharmaceutical Ingredient (API)	DIN	Strength	Lot #	Expiry
Apotex Inc.	APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets)	02305062	500 mg	NV3242	04/2020
				NV3244	04/2020
				NV3245	04/2020
				NV3243	04/2020
				NV3247	04/2020
				NV3248	04/2020
				PX5334	01/2021
				PX5335	01/2021
Ranbaxy Pharmaceuticals Canada Inc.	RAN-Metformin	02269031	500 mg	AJY8006A	05/2020
			500 mg	AJY8007A	05/2020
			500 mg	AJY8005A	05/2020
			500 mg	AJY8005B	05/2020
			500 mg	AJY8008A	05/2020
			850 mg	AJY8005A	05/2020
JAMP Pharma	Metformin	02380196	500 mg	X20283	11/2020
				X20284	11/2020
				X20286	11/2020
				X20287	11/2020
				X20288	11/2020
				Y00225	12/2020
				Y00226	12/2020
				Y00227	12/2020
				Y00228	01/2021
				Y00229	01/2021
				Y00230	01/2021
				Y00231	05/2021
				Y00232	05/2021
				Y01573	05/2021
				Y01574	05/2021
				Y01575	05/2021
				Y01576	05/2021
				Y01577	05/2021
				Y01578	05/2021
				Y01579	06/2021
				Y01580	06/2021
JAMP Pharma	Metformin	02380218	850 mg	X20385	07/2020
				X20386	07/2020
				X19224	10/2020
				X19225	10/2020
				X19226	10/2020

The full details of the Health Canada recall can be found here.

Our firm is seeking compensation for persons who received any of the above-listed drugs. Damages will be sought for individuals who were diagnosed with cancer and other individuals who received the drugs that were recalled. The latter group may be entitled to compensation pursuant to B.C. consumer protection legislation.

If you received any of the above-listed drugs, you may be affected by this class action lawsuit. Please fill out the form below to get in touch with us. Joining our contact list creates no financial obligation and we will keep all the information that you provide to us confidential.

If you have any recalled Metformin please preserve it as we may wish to arrange testing to determine the levels of toxins in the medication.

Metformin Form

Note: You are not obliged to fill in this form to participate in this class action. If you choose to do so, you are not retaining RHE LLP to act on your behalf. Providing the information requested does not make you a client of RHE LLP. All information submitted will be treated as confidential and will only be released as required by law or as you may consent.

I provide my consent and agree herein to receive communications from RHE LLP, which may include announcements regarding class actions, practice updates, newsletters, publications, event invitations or other information that may be of interest. I understand that consent to receive these electronic communications may be withdrawn at any time by emailing reception@rhelaw.com.

Class Action Form

Contact Information

Name *

First

Last

Email *

Phone

FAX

Address (unit no., building/house number, street name)

City/ Town

Province

Postal Code

SUBJECT *

DATE OF BIRTH *

PERSONAL HEALTH NUMBER *

DATE OF PRESCRIPTION *

WHEN DID YOU BECOME AWARE OF THE RECALL? *

DATE THAT YOU SOUGHT MEDICAL TREATMENT FOR YOUR SYMPTOMS

HAVE YOU BEEN DIAGNOSED WITH CANCER? *

ARE YOU AWARE OF THE CANADIAN METFORMIN RECALL? *

WERE YOU TAKING THE DRUGS PRIOR TO THE HEALTH CANADA PUBLIC ADVISORY ON FEBRUARY 5, 2020? *

PLEASE LIST ALL THE SYMPTOMS YOU EXPERIENCED.

OTHER COMMENTS

Consent *

I provide my consent and agree herein to receive communications from RHE LLP, which may include announcements regarding class actions, practice updates, newsletters, publications, event invitations or other information that may be of interest. I understand that I can unsubscribe to these emails at any time. I understand that some of the personal information that I provide may be stored or processed outside of British Columbia and/or Canada, on a US server, and will be kept confidential, subject to the potential that a foreign state may seek to access the data for “lawful access” purposes. If you have any questions about RHE’s policies and practices regarding service providers outside Canada, or about the collection, use, disclosure or storage of personal information by the service providers outside Canada, please contact reception@rhelaw.com.

Custom Captcha *